• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of molecular imaging >Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
【24h】

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

机译：radium-223治疗转移性阉割前列腺癌患者：关于案例介绍的文学更新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Purpose. Radium-223 dichloride (Xofigo?, Bayer HealthCare Pharmaceuticals Inc.) is the first alpha-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC. Clinical trials are currently investigating Radium-223 in additional clinical settings such as earlier asymptomatic disease and in combination with other agents including hormonal therapeutic agents and immunotherapeutic as well as chemotherapeutic agents. Trials are also ongoing in patients with other primary cancers such as breast cancer, thyroid cancer, and renal cancer metastatic to bone. In this article, the physics and radiobiology, as well as a literature update on the use of Radium-223, are provided along with case presentations, aiming at a better appreciation of research data as well as the assimilation of research data into clinical practice.
机译：背景和目的。镭-223二氯化物（Xofigo？，拜耳医疗保健药物Inc.）是FDA批准的第一个α-粒子发射器治疗剂，其在转移阉割前列腺癌患者的症状骨骼事件中有益处和延迟（CRPC ）。 III阶段阶段的近期HOC分析支持以前建立的安全型材以及镭-223的治疗效果和临床结果。目前，镭-223被批准为转移性CRPC的单一代理治疗。目前在额外的临床环境中调查临床-223，例如早期的无症状疾病，以及包括激素治疗剂和免疫治疗剂以及化学治疗剂的其他药剂。试验也在患有其他原发性癌症，如乳腺癌，甲状腺癌和肾癌转移到骨骼的患者中。在本文中，提供了物理和辐射生物学以及关于使用镭223的文献更新，以及案例演示，旨在更好地欣赏研究数据以及研究数据的同化化为临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号